These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34484124)

  • 21. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
    Kaneko S; Oura T; Matsui A; Shingaki T; Takeuchi M
    Endocr J; 2017 Dec; 64(12):1165-1172. PubMed ID: 28904247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
    Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
    Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
    Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
    Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
    Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
    Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
    Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
    BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
    Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
    J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
    Onishi Y; Oura T; Nishiyama H; Ohyama S; Takeuchi M; Iwamoto N
    Endocr J; 2016; 63(3):263-73. PubMed ID: 26698689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.
    Da Porto A; Casarsa V; Colussi G; Catena C; Cavarape A; Sechi L
    Diabetes Metab Syndr; 2020; 14(4):289-292. PubMed ID: 32289741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 32. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riddle MC; Rydén L; Xavier D; Atisso CM; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona-Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw J; Sheu WH; Temelkova-Kurktschiev T;
    Diabetes Obes Metab; 2018 Jan; 20(1):42-49. PubMed ID: 28573765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
    Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
    Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.
    Anderson JE; Thieu VT; Boye KS; Hietpas RT; Garcia-Perez LE
    Postgrad Med; 2016 Nov; 128(8):810-821. PubMed ID: 27488824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
    Giorgino F; Yu M; Haupt A; Milicevic Z; García-Pérez LE
    Diabetes Obes Metab; 2019 Nov; 21(11):2570-2575. PubMed ID: 31364266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Yokoyama H; Haneda M
    Front Endocrinol (Lausanne); 2020; 11():214. PubMed ID: 32390941
    [No Abstract]   [Full Text] [Related]  

  • 37. A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
    Samson SL; Garber AJ
    Curr Diab Rep; 2016 Dec; 16(12):120. PubMed ID: 27766579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
    Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
    Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
    Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.